Key corporate and policy moves on Apr. 24

A series of corporate announcements and policy actions on April 24, 2026, spanned healthcare, energy, financial markets, and digital assets. Companies reported strategic moves and outlooks, while U.S. authorities undertook action involving cryptocurrency allegedly linked to Iran.

HCA Healthcare projected volume growth of 2% to 3% while affirming its outlook for 2026. The company highlighted that it expects to face an exchange-related headwind estimated between $600 million and $900 million, but it maintained its existing guidance for the year despite that impact.

The projections suggest HCA is planning for moderate growth in patient volumes while absorbing a sizable foreign-exchange effect. The company did not indicate any changes to its broader financial objectives for 2026 in light of the currency headwind.

On April 24, 2026, it was reported that the Trump administration froze $344 million in cryptocurrency allegedly connected to Iran. The action targets digital assets that U.S. officials believe are linked to Iranian interests, according to the report.

The reported freeze highlights continuing U.S. enforcement efforts in the digital asset space, focusing on funds suspected of connections to sanctioned parties or jurisdictions. The report did not provide further detail on the specific cryptocurrencies or platforms involved.

In a separate development, investor Scott Bessent defended the U.S. decision to participate in currency swaps with allies in the Persian Gulf. His comments supported the policy of engaging in swap arrangements with those regional partners.

Bessent’s defense of the swaps points to ongoing debate over the role of U.S. dollar liquidity facilities and currency cooperation with energy-producing allies in the Gulf region.

Energy and chemicals company Phillips 66 received an upgrade at Morgan Stanley (MS). The investment bank cited upside potential in the company’s chemicals business and an attractive relative valuation as reasons for the change in rating.

The upgrade reflects Morgan Stanley (MS)’s view that Phillips 66’s chemicals segment and current pricing versus peers present an appealing opportunity, according to the report. No additional financial details were disclosed in the summary.

BridgeBio Pharma shares gained after a report of a settlement in a patent dispute with Pfizer (PFE) over Vyndamax. The move in the stock followed news that the companies had reached a settlement in the case, according to the report.

Separately, Humacyte announced it had regained rights outside the United States to its Symvess product from Fresenius Medical Care (FMEd). The change returns ex-U.S. control of Symvess to Humacyte, altering the prior rights arrangement between the two companies.

BMO announced its monthly distributions for May for its exchange-traded funds. The announcement confirmed the upcoming cash flows that holders of the firm’s ETFs can expect in that month.

In another income-focused move, the IA Clarington Agile Global Total Return Income Fund ETF Series declared a dividend of 0.0448 Canadian dollars. The declaration sets the per-unit payout investors will receive from this ETF.

In the U.S. market, a preview of MSA Safety’s first-quarter dividend indicated that the company’s 25-year dividend growth streak is set to continue. The report framed the upcoming Q1 dividend as extending the company’s long-running pattern of annual increases.